Научно-практический журнал
[About us] Journal 'Cytokines & Inflammation'

197376, Санкт-Петербург, ул. Акад. Павлова, д. 12,
Институт экспериментальной медицины РАМН
Тел.: (812) 234 16 69, +7 921 984 11 30, +7 921 909 55 49
Факс: (812) 234 94 89
E-mail:
Web: cytokines.ru


  


Year 2007
Number 1 Number 2
Number 3 Number 4 NEW

About journal

Archive

Columns
Subscription

Rules for authors

Contact us

Search

Site map

Our partners:

https://pornoseksxxx.com/

Русский языкEnglish language
Site map Contact us

Contents | Next article | Previous article

Journal 'Cytokines & inflammation', 2007, No. 3

Subscribe for 2008 year

Order this issue

Order PDF of this article

Original Articles

Number 3'2007

SERUM CYTOKINE CONCENTRATIONS IN ONCOLOGIC PATIENTS DURING IMMUNO- AND POLYCHEMOTHERAPIES WITH APPLICATION OF HUMAN ALPHA-FETOPROTEIN

S.J. Rodionov, V.A. Chereshnev, E.G. Orlova, L.A. Taranenko, S.V. Sibiryak, O.A. Orlov, N.N. Shur, O.A. Krapivina, D.A. Sukhovaja

The concentrations of IL-2, IL-4, IL-6, IL-10, IFNα and TNFα in serum of 46 oncologic patients (breast, stomach, colorectal cancer, lymphosarcoma) before and after treatment with alpha-fetoprotein (Profetalα) and Profetalα in combination with polychemotherapy was studied. It is established, that after treatment with Profetalα application the levels of IL-2 and IFNα were increased while concentrations of IL-6 and IL-10 were decreased which indirectly suggests that alpha-fetoprotein administration promotes the shift in cytokine balance towards cell-mediated immune responses of Th1 type. Moreover, the concentration of IFNα in serum of these patients was significantly higher than in oncologic patients of other groups and also in healthy donors. On the contrary, in patients received polychemotherapy the IL-2 concentration decreased, whereas in patients treated by polychemotherapy plus Profetalα the differences between IL-2 level before and after treatment were not revealed. Thus, the further studying of possibilities of immunotherapeutic Profetalα administration in complex treatment of oncologic diseases seems to be important. (Cytokines and Inflammation. 2007. Vol. 6, No. 3. P. 36-39.)

Contents | Next article | Previous article


© 2007 Cytokines and inflammation